Johnson & Johnson CEO on Why He’s Not Focusing on GLP-1s

Bloomberg Television2 hours ago0:43

Johnson & Johnson CEO Joaquin Duato explains why the healthcare giant is skipping the obesity drug boom to focus on curing cancer and addressing dementia. He sat down with David M Rubenstein. For more, watch Peer to Peer Conversations #health #glp1

Trading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.